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Activation of NMDA receptors is involved in some forms
of learning. However, the molecular events by which
NMDA receptors modulate learning remain unclear. Acti-
vation of NMDA receptors leads to increased intracellular
calcium which binds to calmodulin and activates neuro-
nal nitric oxide synthase, increasing the formation of
nitric oxide (NO) which, in turn, activates soluble guan-
ylate cyclase. This leads to increased formation and release
to the extracellular space of cGMP. We propose that acti-
vation of this glutamate-NO-cGMP pathway and the
release of cGMP to the extracellular space are involved in
the process of learning a Y maze conditional discrimina-
tion task.
We analyzed by in vivo brain microdialysis the function of
the glutamate-NO-cGMP pathway in cerebellum in vivo
in different animal models and found that there is an
excellent correlation between the function of the pathway
and the ability of rats to learn the Y maze conditional dis-
crimination task.
Patients with hepatic encephalopathy show impaired
intellectual capacity. The underlying molecular mecha-
nism remains unknown. Rats with portacaval anastomo-
sis or with hyperammonemia without liver failure
(animal models of hepatic encephalopathy) show
impaired learning ability and impaired function of the
glutamate-NO-cGMP pathway. We hypothesised that
impairment of learning in liver failure and hyperammon-
emia would be due to the impairment of the function of
the pathway and that its pharmacological manipulation
to increase cGMP content could restore learning ability. It
is shown, by in vivo brain microdialysis, that chronic
intracerebral administration of zaprinast, or oral adminis-
tration of sildenafil, two inhibitors of the phosphodieste-
rase that degrades cGMP, normalizes the glutamate-NO-
cGMP pathway function and extracellular cGMP in brain
in vivo in rats with portacaval anastomosis or with hyper-
ammonemia. Moreover, zaprinast and sildenafil restored
the ability of these rats to learn the conditional discrimi-
nation task.
Intracerebral administration of cGMP, that does not enter
into the cells, also restores learning, indicating that extra-
cellular cGMP modulates learning of this task. In conclu-
sion, the results reported indicate that impairment of
learning ability in rats with chronic liver failure or with
hyperammonemia is due to impairment of the glutamate-
NO-cGMP pathway and that pharmacological manipula-
tion of the pathway maybe useful for the clinical treat-
ment of the impairment in intellectual function in
patients with hepatic encephalopathy.
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